KorrekturOpen Access
Correction to “Efficacy and safety of teclistamab in triple‐class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort”
Cancer · 15.08.2026 · 132 (16)
DOI: 10.1002/cncr.70508 ↗Kurz gefasst
Korrektur in der Zeitschrift Cancer, online erschienen am 13.08.2026. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2026). Correction to “Efficacy and safety of teclistamab in triple‐class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort”. Cancer, 132(16). https://doi.org/10.1002/cncr.70508
Vancouver
Correction to “Efficacy and safety of teclistamab in triple‐class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort”. Cancer. 2026;132(16). doi:10.1002/cncr.70508
BibTeX
@article{euvimed2026,
title = {Correction to “Efficacy and safety of teclistamab in triple‐class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort”},
journal = {Cancer},
year = {2026},
volume = {132},
number = {16},
doi = {10.1002/cncr.70508}
}
EUVIMED